Grazia Graziani

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2500796/publications.pdf

Version: 2024-02-01

154	5,496	81900	102487
papers	citations	39 h-index	66 g-index

155	155	155	7580
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Involvement of the Mismatch Repair System in Temozolomide-Induced Apoptosis. Molecular Pharmacology, 1998, 54, 334-341.	2.3	233
2	EGFR heterogeneity and implications for therapeutic intervention in glioblastoma. Neuro-Oncology, 2018, 20, 743-752.	1.2	210
3	Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid. Nutrients, 2018, 10, 1756.	4.1	178
4	Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacological Research, 2005, 52, 25-33.	7.1	170
5	Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clinical Cancer Research, 2003, 9, 5370-9.	7.0	160
6	Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors. Cancers, 2018, 10, 487.	3.7	154
7	Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacological Research, 2002, 45, 73-85.	7.1	134
8	Clinical perspectives of PARP inhibitors. Pharmacological Research, 2005, 52, 109-118.	7.1	130
9	Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. European Journal of Cancer, 2007, 43, 2124-2133.	2.8	128
10	Role of VEGFs/VEGFR-1 Signaling and Its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models. International Journal of Molecular Sciences, 2020, 21, 1388.	4.1	127
11	Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors. Pharmacological Research, 2018, 136, 97-107.	7.1	126
12	Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer. Pharmacological Research, 2012, 65, 9-22.	7.1	119
13	PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy. Oncogene, 2010, 29, 6280-6293.	5.9	103
14	Inhibition of poly(ADPâ€ribose) polymerase prevents irinotecanâ€induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. FASEB Journal, 2006, 20, 1709-1711.	0.5	97
15	Challenging resistance mechanisms to therapies for metastatic melanoma. Trends in Pharmacological Sciences, 2013, 34, 656-666.	8.7	90
16	Role of beauty treatment in the spread of parenterally transmitted hepatitis viruses in Italy. Journal of Medical Virology, 2004, 74, 216-220.	5.0	84
17	Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood, 2002, 99, 2241-2244.	1.4	83
18	Recent Approaches to Improve the Antitumor Efficacy of Temozolomide. Current Medicinal Chemistry, 2009, 16, 245-257.	2.4	80

#	Article	IF	Citations
19	EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation. Neuro-Oncology, 2016, 18, 1644-1655.	1.2	78
20	Reduced Proficiency in Homologous Recombination Underlies the High Sensitivity of Embryonal Carcinoma Testicular Germ Cell Tumors to Cisplatin and Poly (ADP-Ribose) Polymerase Inhibition. PLoS ONE, 2012, 7, e51563.	2.5	78
21	Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth. Nutrients, 2016, 8, 744.	4.1	76
22	PARP-1 Modulates Amyloid Beta Peptide-Induced Neuronal Damage. PLoS ONE, 2013, 8, e72169.	2.5	70
23	CRH Inhibits Cell Growth of Human Endometrial Adenocarcinoma Cells via CRH-Receptor 1-Mediated Activation of cAMP-PKA Pathway. Endocrinology, 2002, 143, 807-813.	2.8	64
24	Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide. BMC Cancer, 2014, 14, 151.	2.6	64
25	Saffron and Its Major Ingredientsâ€™ Effect on Colon Cancer Cells with Mismatch Repair Deficiency and Microsatellite Instability. Molecules, 2021, 26, 3855.	3.8	64
26	The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges. , 2020, 213, 107579.		62
27	Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G2/M cell accumulation induced by temozolomide in malignant glioma cells. Glia, 2002, 40, 44-54.	4.9	61
28	Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk?. Pharmacological Research, 2007, 55, 359-369.	7.1	61
29	Neuropilin-1 as Therapeutic Target for Malignant Melanoma. Frontiers in Oncology, 2015, 5, 125.	2.8	61
30	Requirement of phospholipase C-catalyzed hydrolysis of phosphatidylcholine for maturation of Xenopus laevis oocytes in response to insulin and ras p21. Journal of Biological Chemistry, 1991, 266, 6825-9.	3.4	57
31	Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds. Leukemia, 1999, 13, 901-909.	7.2	56
32	Inhibition of O⁶-Alkylguanine DNA-Alkyltransferase or Poly(ADP-ribose) Polymerase Increases Susceptibility of Leukemic Cells to Apoptosis Induced by Temozolomide. Molecular Pharmacology, 1997, 52, 249-258.	2.3	53
33	BRCA1, PARP1 and Î³H2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 462-472.	3.8	53
34	Pharmacological Strategies to Increase the Antitumor Activity of Methylating Agents. Current Medicinal Chemistry, 2002, 9, 1285-1301.	2.4	52
35	Cilengitide downmodulates invasiveness and vasculogenic mimicry of neuropilin 1 expressing melanoma cells through the inhibition of Î±vÎ²5 integrin. International Journal of Cancer, 2015, 136, E545-58.	5.1	49
36	High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro. Oncotarget, 2017, 8, 32550-32565.	1.8	47

#	Article	IF	Citations
37	Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype. Molecular and Cellular Endocrinology, 2007, 264, 44-49.	3.2	45
38	Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment. Pharmacological Research, 2022, 175, 105997.	7.1	43
39	Inhibition of Telomerase Increases Resistance of Melanoma Cells to Temozolomide, but Not to Temozolomide Combined with Poly (ADP-Ribose) Polymerase Inhibitor. Molecular Pharmacology, 2003, 63, 192-202.	2.3	42
40	Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity. European Journal of Cancer, 2008, 44, 1302-1314.	2.8	40
41	Exploiting Microglial Functions for the Treatment of Glioblastoma. Current Cancer Drug Targets, 2017, 17, 267-281.	1.6	40
42	Poly (ADP-ribose) polymerase inhibitor increases apoptosis and reduces necrosis induced by a DNA minor groove binding methyl sulfonate ester. Cell Death and Differentiation, 2001, 8, 817-828.	11.2	39
43	Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse into Novel Therapeutic Approaches for Metastatic Melanoma. Cancers, 2020, 12, 3401.	3.7	39
44	Chimeric Molecules between Keratinocyte Growth Factor and Basic Fibroblast Growth Factor Define Domains That Confer Receptor Binding Specificities. Journal of Biological Chemistry, 1995, 270, 29813-29818.	3.4	37
45	Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide. European Journal of Cancer, 2005, 41, 2948-2957.	2.8	37
46	The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells. Journal of Experimental and Clinical Cancer Research, 2017, 36, 106.	8.6	36
47	Placenta growth factor and neuropilin-1 collaborate in promoting melanoma aggressiveness. International Journal of Oncology, 2016, 48, 1581-1589.	3.3	34
48	On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment. Chemotherapy, 2019, 64, 62-80.	1.6	34
49	Role of VEGFRâ€1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib. Journal of Cellular and Molecular Medicine, 2020, 24, 465-475.	3.6	34
50	The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. Oncology Reports, 2008, 19, 1039-43.	2.6	34
51	Emergence of Double-Positive CD4/CD8 Cells from Adult Peripheral Blood Mononuclear Cells Infected with Human T Cell Leukemia Virus Type I (HTLV-I). Cellular Immunology, 1993, 149, 376-389.	3.0	33
52	The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma. European Journal of Cancer, 2011, 47, 1219-1230.	2.8	32
53	NF-ÎºB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug. Journal of Translational Medicine, 2012, 10, 252.	4.4	32
54	Mutation of the mismatch repair genehMSH2 andhMSH6 in a human T-cell leukemia line tolerant to methylating agents. , 1998, 23, 159-166.		31

#	Article	IF	Citations
55	Rifampin Increases Cytokine-Induced Expression of the CD1b Molecule in Human Peripheral Blood Monocytes. Antimicrobial Agents and Chemotherapy, 1998, 42, 550-554.	3.2	31
56	PARP-1 inhibition to treat cancer, ischemia, inflammation. Pharmacological Research, 2005, 52, 1-4.	7.1	30
57	Strategies to improve ellagic acid bioavailability: from natural or semisynthetic derivatives to nanotechnological approaches based on innovative carriers. Nanotechnology, 2020, 31, 382001.	2.6	30
58	Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome. Oncotarget, 2017, 8, 13223-13239.	1.8	30
59	Evidence of the crucial role of the linker domain on the catalytic activity of human topoisomerase I by experimental and simulative characterization of the Lys681Ala mutant. Nucleic Acids Research, 2009, 37, 6849-6858.	14.5	29
60	Glucocorticoid-Induced Tumor Necrosis Factor Receptor Family-Related Ligand Triggering Upregulates Vascular Cell Adhesion Molecule-1 and Intercellular Adhesion Molecule-1 and Promotes Leukocyte Adhesion. Journal of Pharmacology and Experimental Therapeutics, 2013, 347, 164-172.	2.5	29
61	A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib. Biochemical Pharmacology, 2015, 95, 16-27.	4.4	29
62	Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells. Cell Death and Differentiation, 2001, 8, 457-469.	11.2	28
63	Cisplatin Increases Sensitivity of Human Leukemic Blasts to Triazene Compounds. Journal of Chemotherapy, 1995, 7, 224-229.	1.5	26
64	Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components. Cancer Chemotherapy and Pharmacology, 2001, 47, 361-369.	2.3	26
65	Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2. Biochemical Pharmacology, 2020, 180, 114169.	4.4	26
66	Stem cell factor activates telomerase in mouse mitotic spermatogonia and in primordial germ cells. Journal of Cell Science, 2002, 115, 1643-1649.	2.0	26
67	Expression of the soluble vascular endothelial growth factor receptor-1 in cutaneous melanoma: role in tumour progression. British Journal of Dermatology, 2011, 164, 1061-1070.	1.5	25
68	PDIA3 Expression in Glioblastoma Modulates Macrophage/Microglia Pro-Tumor Activation. International Journal of Molecular Sciences, 2020, 21, 8214.	4.1	25
69	Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding. Oncotarget, 2016, 7, 72868-72885.	1.8	25
70	Lead Discovery of Dual G-Quadruplex Stabilizers and Poly(ADP-ribose) Polymerases (PARPs) Inhibitors: A New Avenue in Anticancer Treatment. Journal of Medicinal Chemistry, 2017, 60, 3626-3635.	6.4	24
71	The Antiâ€“Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody D16F7 Inhibits Glioma Growth and Angiogenesis In Vivo. Journal of Pharmacology and Experimental Therapeutics, 2018, 364, 77-86.	2.5	24
72	Valproic Acid Increases the Stimulatory Effect of Estrogens on Proliferation of Human Endometrial Adenocarcinoma Cells. Endocrinology, 2003, 144, 2822-2828.	2.8	23

#	Article	IF	Citations
73	Targeted Therapy for Brain Tumours: Role of PARP Inhibitors. Current Cancer Drug Targets, 2012, 12, 218-236.	1.6	23
74	VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody. Journal of Experimental and Clinical Cancer Research, 2021, 40, 320.	8.6	23
75	The poly(ADP-ribose) polymerase inhibitor olaparib induces up-regulation of death receptors in primary acute myeloid leukemia blasts by NF-ÎºB activation. Cancer Letters, 2018, 423, 127-138.	7.2	22
76	Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma. Pharmacological Research, 2020, 159, 104957.	7.1	22
77	Decline of natural cytotoxicity of human lymphocytes following infection with human T-cell leukemia/lymphoma virus (HTLV). Leukemia Research, 1985, 9, 349-355.	0.8	21
78	Influence of Mycobacterium bovis Bacillus Calmette Guèrin on In Vitro Induction of CD1 Molecules in Human Adherent Mononuclear Cells. Infection and Immunity, 2001, 69, 7461-7470.	2.2	21
79	Inhibition of endothelial cell migration and angiogenesis by a vascular endothelial growth factor receptor-1 derived peptide. European Journal of Cancer, 2008, 44, 1914-1921.	2.8	21
80	Platelet-derived growth factor C and calpain-3 are modulators of human melanoma cell invasiveness. Oncology Reports, 2013, 30, 2887-2896.	2.6	20
81	CRH Inhibits Cell Growth of Human Endometrial Adenocarcinoma Cells via CRH-Receptor 1-Mediated Activation of cAMP-PKA Pathway. Endocrinology, 2002, 143, 807-813.	2.8	20
82	Stem cell factor activates telomerase in mouse mitotic spermatogonia and in primordial germ cells. Journal of Cell Science, 2002, 115, 1643-9.	2.0	20
83	Cytotoxic and clastogenic effects of a DNA minor groove binding methyl sulfonate ester in mismatch repair deficient leukemic cells. Leukemia, 2000, 14, 1451-1459.	7.2	19
84	PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets. Frontiers in Oncology, 2013, 3, 279.	2.8	19
85	Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders. Biochemical Pharmacology, 2019, 167, 133-148.	4.4	19
86	Depression of early phase of HTLV-I infection in vitro mediated by human beta-interferon. British Journal of Cancer, 1988, 57, 481-488.	6.4	18
87	Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent. Current Cancer Drug Targets, 2010, 10, 368-383.	1.6	18
88	Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells. Biochemical Pharmacology, 2011, 81, 194-202.	4.4	18
89	Valproic acid activity in androgen-sensitive and -insensitive human prostate cancer cells. International Journal of Oncology, 1992, 32, 1293-1303.	3.3	18
90	High-Dose Vitamin C: Preclinical Evidence for Tailoring Treatment in Cancer Patients. Cancers, 2021, 13, 1428.	3.7	17

#	Article	IF	Citations
91	Platelet-derived growth factor-C promotes human melanoma aggressiveness through activation of neuropilin-1. Oncotarget, 2017, 8, 66833-66848.	1.8	17
92	Apoptotic and genotoxic effects of a methyl sulfonate ester that selectively generates N3-methyladenine and poly(ADP-ribose) polymerase inhibitors in normal peripheral blood lymphocytes. Cancer Chemotherapy and Pharmacology, 2002, 49, 217-224.	2.3	16
93	Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential. , 2022, 236, 108106.		16
94	Generation of an immortalized human endothelial cell line as a model of neovascular proliferating endothelial cells to assess chemosensitivity to anticancer drugs. International Journal of Oncology, 2005, 27, 525.	3.3	15
95	Role of the mismatch repair system and p53 in the clastogenicity and cytotoxicity induced by bleomycin. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2006, 594, 63-77.	1.0	15
96	At the Cutting Edge against Cancer: A Perspective on Immunoproteasome and Immune Checkpoints Modulation as a Potential Therapeutic Intervention. Cancers, 2021, 13, 4852.	3.7	15
97	Primary cultures of microglial cells for testing toxicity of anticancer drugs. Toxicology Letters, 2004, 148, 91-94.	0.8	14
98	MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination. Cancer Chemotherapy and Pharmacology, 2013, 72, 117-125.	2.3	14
99	Modulation of GDF11 expression and synaptic plasticity by age and training. Oncotarget, 2017, 8, 57991-58002.	1.8	14
100	Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes. Cancers, 2019, 11, 1373.	3.7	13
101	Generation of an immortalized human endothelial cell line as a model of neovascular proliferating endothelial cells to assess chemosensitivity to anticancer drugs. International Journal of Oncology, 2005, 27, 525-35.	3.3	13
102	The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. Oncology Reports, 2008, , .	2.6	12
103	Pharmacological inhibition of poly(ADP-ribose) polymerase activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells. International Journal of Oncology, 2009, 34, 861-72.	3.3	12
104	Effect of prostaglandin A1 on proliferation and telomerase activity of human melanoma cells in vitro. Melanoma Research, 1998, 8, 323-328.	1.2	11
105	In vitro infection of CD4+ T lymphocytes with HTLV-I generates immortalized cell lines coexpressing lymphoid and myeloid cell markers. Leukemia, 1999, 13, 222-229.	7.2	11
106	hMSH3 overexpression and cellular response to cytotoxic anticancer agents. Carcinogenesis, 2001, 22, 1131-1137.	2.8	11
107	N3-Methyladenine Induces Early Poly(ADP-Ribosylation), Reduction of Nuclear Factor-Î¹B DNA Binding Ability, and Nuclear Up-Regulation of Telomerase Activity. Molecular Pharmacology, 2005, 67, 572-581.	2.3	11
108	Common fragile sites in colon cancer cell lines: Role of mismatch repair, RAD51 and poly(ADP-ribose) polymerase-1. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2011, 712, 40-48.	1.0	11

#	Article	IF	Citations
109	Beneficial and Detrimental Effects of Antiretroviral Therapy on HIV-Associated Immunosenescence. Chemotherapy, 2018, 63, 64-75.	1.6	11
110	Defective proteasome biogenesis into skin fibroblasts isolated from Rett syndrome subjects with MeCP2 non-sense mutations. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165793.	3.8	11
111	Adjuvant treatment of breast cancer: A pilot immunochemotherapy study with CMF, interleukin-2 and interferon alpha. Cancer Immunology, Immunotherapy, 1998, 47, 157-166.	4.2	10
112	Effect of rifampin on CD1b expression and double-negative T cell responses against mycobacteria-dertved glycolipid antigen. Life Sciences, 1998, 63, 985-994.	4.3	10
113	Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan. International Journal of Oncology, 2013, 43, 210-218.	3.3	10
114	Vascular endothelial growth factor receptor 1 in glioblastomaâ€‘associated microglia/macrophages. Oncology Reports, 2020, 43, 2083-2092.	2.6	10
115	Effect of hydrocortisone on human natural killer activity and its modulation by beta interferon. International Journal of Immunopharmacology, 1988, 10, 687-694.	1.1	9
116	CYTOKINE-INDUCED EXPRESSION OF CD1b MOLECULES BY PERIPHERAL BLOOD MONOCYTES: INFLUENCE OF 3â€²-AZIDO-3â€²-DEOXYTHYMIDINE. Pharmacological Research, 1997, 35, 135-140.	7.1	9
117	Bacillus Calmette-Guerin Down-Regulates CD1b Induction by Granulocyte-Macrophage Colony Stimulating Factor in Human Peripheral Blood Monocytes. Journal of Chemotherapy, 2001, 13, 52-58.	1.5	9
118	Corticotropin-releasing hormone receptor-1 in human endometrial cancer. Oncology Reports, 2006, 15, 375-9.	2.6	9
119	Placenta growth factor induces melanoma resistance to temozolomide through a mechanism that involves the activation of the transcription factor NF-Î°B. International Journal of Oncology, 2011, 38, 241-7.	3.9	9
120	Transient HTLV-I Infection of a Human Glioma Cell Line Following Cell-Free Exposure. Virology, 1993, 197, 767-769.	2.4	8
121	A Novel Method for Monitoring Response to Chemotherapy Based on the Detection of Circulating Cancer Cells: A Case Report. Journal of Chemotherapy, 2002, 14, 412-416.	1.5	7
122	Incidence of Parenterally Transmitted Acute Viral Hepatitis Among Healthcare Workers in Italy. Infection Control and Hospital Epidemiology, 2007, 28, 629-632.	1.8	7
123	Poly(ADP-Ribose) Polymerase Inhibitors for Arsenic Trioxideâ€“Resistant Acute Promyelocytic Leukemia: Synergistic In Vitro Antitumor Effects with Hypomethylating Agents or High-Dose Vitamin C. Journal of Pharmacology and Experimental Therapeutics, 2021, 377, 385-397.	2.5	7
124	The Effects of Association of Topical Polydatin Improves the Preemptive Systemic Treatment on EGFR Inhibitors Cutaneous Adverse Reactions. Journal of Clinical Medicine, 2021, 10, 466.	2.4	7
125	Staurosporine Increases Carcinoembryonic Antigen Expression in a Human Colon Cancer Cell Line. Journal of Chemotherapy, 2000, 12, 167-172.	1.5	6
126	Clinical applications of telomerase in cancer treatment. Drug Resistance Updates, 2000, 3, 161-170.	14.4	6

#	Article	IF	Citations
127	Treatment of peripheral blood with staurosporine increases detection of circulating carcinoembryonic antigen positive tumor cells. International Journal of Cancer, 2002, 100, 119-121.	5.1	6
128	Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. International Journal of Oncology, 2005, 26, 415.	3.3	6
129	Inhibition of homologous recombination by treatment with BVDU (brivudin) or by RAD51 silencing increases chromosomal damage induced by bleomycin in mismatch repair-deficient tumour cells. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009, 664, 39-47.	1.0	6
130	Development of a NovelIn VitroChemosensitivity Assay: Telomerase as a Possible Marker of Tumor Cell Survival. Journal of Chemotherapy, 1996, 8, 394-398.	1.5	5
131	Pharmacological modulation of carcinoembryonic antigen in human cancer cells: studies with staurosporine. International Immunopharmacology, 2002, 2, 641-651.	3.8	5
132	BCG-infected adherent mononuclear cells release cytokines that regulate group 1 CD1 molecule expression. International Immunopharmacology, 2007, 7, 321-332.	3.8	5
133	Drug-induced xenogenization of tumors: A possible role in the immune control of malignant cell growth in the brain?. Pharmacological Research, 2018, 131, 1-6.	7.1	5
134	Detection of circulating tumor cells is improved by drug-induced antigen up-regulation: preclinical and clinical studies. Anticancer Research, 2010, 30, 4721-30.	1.1	5
135	Exogenous Control of the Expression of Group I CD1 Molecules Competent for Presentation of Microbial Nonpeptide Antigens to Human T Lymphocytes. Clinical and Developmental Immunology, 2011, 2011, 1-27.	3.3	4
136	Effects of Glutathione Transferase-Targeting Nitrobenzoxadiazole Compounds in Relation to PD-L1 Status in Human Melanoma Cells. Chemotherapy, 2019, 64, 138-145.	1.6	4
137	hTERT Transduction Extends the Lifespan of Primary Pediatric Low-Grade Glioma Cells While Preserving the Biological Response to NGF. Pathology and Oncology Research, 2021, 27, 612375.	1.9	4
138	In vitro combined effects of human interferons and interleukin-2 on natural cell-mediated cytotoxicity. International Journal of Immunopharmacology, 1993, 15, 1-10.	1.1	3
139	Temozolomide: An Update on Pharmacological Strategies to Increase its Antitumour Activity. Medicinal Chemistry Reviews Online, 2004, 1, 141-150.	0.1	3
140	Mutations of human DNA topoisomerase I at poly(ADP-ribose) binding sites: modulation of camptothecin activity by ADP-ribose polymers. Journal of Experimental and Clinical Cancer Research, 2014, 33, 71.	8.6	3
141	Poly(ADP-ribose) polymerase inhibitor olaparib hampers placental growth factor-driven activation of myelomonocytic cells. Oncology Reports, 2018, 39, 2261-2269.	2.6	3
142	DNA inhibitors for the treatment of brain tumors. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 195-207.	3.3	3
143	Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab. Experientia Supplementum (2012), 2022, 113, 295-350.	0.9	3
144	Insulin-Degrading Enzyme Is a Non Proteasomal Target of Carfilzomib and Affects the 20S Proteasome Inhibition by the Drug. Biomolecules, 2022, 12, 315.	4.0	3

#	Article	IF	Citations
145	Valproic acid activity in androgen-sensitive and -insensitive human prostate cancer cells. International Journal of Oncology, 2008, , .	3.3	2
146	Telomerase as a potential anticancer target: growth inhibition and genomic instability. Drug Resistance Updates, 2000, 3, 3-6.	14.4	1
147	Corticotropin-releasing hormone receptor-1 in human endometrial cancer. Oncology Reports, 2006, 15, 375.	2.6	1
148	Neuropilin-1 expressing melanoma cells as a model to study the aggressiveness of metastatic melanoma. Journal of Translational Medicine, 2015, 13, P6.	4.4	1
149	Editorial. Chemotherapy, 2016, 61, 1-2.	1.6	0
150	Influence of Mycobacterium bovis Bacillus Calmette Guèrin on In Vitro Induction of CD1 Molecules in Human Adherent Mononuclear Cells. Infection and Immunity, 2002, 70, 2739-2739.	2.2	0
151	Abstract C51: High sensitivity of testicular germ cell tumors to PARP inhibitor olaparib alone and in combination with cisplatin. , 2011, , .		0
152	Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab. , 2014, , 233-258.		0
153	Abstract C09: Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to cisplatin and poly (ADP-ribose) polymerase inhibition. , 2013, , .		0
154	Macrophages/microglia in glioblastoma: a Zelig-like story of changing phenotypes. Translational Cancer Research, 2017, 6, S1101-S1103.	1.0	0